



Product Information

Roar Ex Vivo CETP Activity Assay, 92 assays

Cat. No. RB-EVAK version C100

U.S. Pat. Nos. 7,279,297; 7,642,065, European Pat. No. 1492880, Japanese Pat. No. 4339702 and Canadian Pat. No. 2480439


Assay Method:	Fluorometric
Number of Assays:	92 assays in 105 µl total assay volume
Assay Components:	Reagent A Reagent B Assay Buffer Blank
Instrumentation:	Fluorescence microplate reader (excitation: 465 nm / emission 535 nm)

Introduction

Cholesteryl ester transfer protein (CETP), present in normal human plasma, transfers neutral lipids among the different classes of lipoproteins (HDL, LDL, VLDL). CETP plays an important role in lipoprotein metabolism and influences the reverse cholesterol transport pathway. The **Roar Ex Vivo CETP Activity Assay** is a unique assay that eliminates the dilution factor associated with conventional CETP activity assays. The method is performed with all plasma components at near physiological concentration, measuring CETP activity *in vitro* with the effect of known endogenous inhibitors (apo-C1, for example) as occurs *in vivo*. The assay has been extensively validated and used by pharmaceutical companies in the CETP inhibitor human clinical trials for many years. This assay has piqued the interest of epidemiological researchers and in a large population study the results from this assay (and our PLTP activity assay) are a significant biomarker for CVD in men.

The **Roar Ex Vivo CETP Activity Assay** includes proprietary substrates that enable the detection of CETP-mediated transfer of neutral lipid among the substrates. The CETP transfer activity results in an increase in fluorescence intensity. The combined assay substrate volume is 4.8% of the total assay volume and the plasma volume is 95.2% of the assay volume. The assay is incubated for 90 minutes at 37°C.

Please contact us for more information about this assay, or to request a complete protocol.



Roar Biomedical, Inc., Audubon Biomedical Center, 3960 Broadway, New York, NY 10032 USA
Tel: +1 (212) 280-2983 ■ Fax: +1 (212) 280-2968 ■ info@roarbiomedical.com ■ www.roarbiomedical.com

This product is the subject of U.S. Pat. Nos. 7,279,297; 7,642,065, European Pat. No. 1492880, Japanese Pat. No. 4339702 and Canadian Pat. No. 2480439 owned by Roar Biomedical, Inc.

©2002-2014 Roar Biomedical, Inc. All rights reserved. This information is subject to change without notice.

RB-EVAK Cited References (2009-2014)

Roar Ex Vivo CETP Activity Assay Kit

1. Han S, LeVoci L, Fischer P, et al. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein. *BBA-Molecular and Cell Biology of Lipids*. 2013;1831(4):825-833.
2. Robins SJ, Lyass A, Brocchia RW, Massaro JM, Vasan RS. Plasma lipid transfer proteins and cardiovascular disease. the framingham heart study. *Atherosclerosis*. 2013;228(1):230-236.
3. Siebel AL, Natoli AK, Yap FY, et al. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. *Circ Res*. 2013;113(2):167-175.
4. Bentley DD. Evidence of a Drug–Drug interaction linked to inhibition of ester hydrolysis by orlistat. *J Cardiovasc Pharmacol*. 2012;60(4):390-396.
5. Sarich TC, Connelly MA, Schranz DB, et al. Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans. *Int J Clin Pharmacol Ther*. 2012;50(8):584-594.
6. Castro-Perez J, Briand F, Gagen K, et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in syrian golden hamsters. *J Lipid Res*. 2011;52(11):1965-1973.
7. Derks M, Anzués-Cabrera J, Turnbull L, Phelan M. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: A randomized, double-blind, placebo-controlled, phase I study. *Clinical Drug Investigation*. 2011;31(5):325-335.
8. Connelly MA, Parry TJ, Giardino EC, et al. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. *J Cardiovasc Pharmacol*. 2010;55(5):459-468.
9. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. *J Lipid Res*. 2010;51(12):3443-3454.
10. Kuo G, Rano T, Pelton P, et al. Design, synthesis, and biological evaluation of (2R,αS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-α-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor. *J Med Chem* [supporting information: jm801319d_si_001.pdf]. 2009;52(6):1768-1772.

Roar Biomedical, Inc., Audubon Biomedical Center, 3960 Broadway, New York, NY 10032 USA
Tel: +1 (212) 280-2983 ■ Fax: +1 (212) 280-2968 ■ info@roarbiomedical.com ■ www.roarbiomedical.com

This product is the subject of U.S. Pat. Nos. 7,279,297; 7,642,065, European Pat. No. 1492880,
Japanese Pat. No. 4339702 and Canadian Pat. No. 2480439 owned by Roar Biomedical, Inc.

©2002-2014 Roar Biomedical, Inc. All rights reserved. This information is subject to change without notice.